Strategies for management of patients with, or at risk for, medication-related osteonecrosis of
the jaw (MRONJ) were set forth in the American Association of Oral and Maxillofacial …

Bisphosphonates (BPs) are the most commonly used medications for osteoporosis. This
ASBMR report provides guidance on BP therapy duration with a risk‐benefit perspective …

Background Long-term safety and efficacy of osteoporosis treatment are important because
of the chronic nature of the disease. We aimed to assess the long-term safety and efficacy of …

Medication-related osteonecrosis of the jaw (MRONJ) is primarily an adverse side effect of
denosumab or bisphosphonates (particularly when used at high doses to prevent skeletal …

The aim of this systematic review was to answer the question: What are the treatments
available for bisphosphonate-related osteonecrosis of the jaws (BRONJ) and their …

Background Osteonecrosis of the jaw (ONJ) has been reported in patients receiving
bisphosphonates for metastatic bone disease. ONJ incidence, risk factors, and outcomes …

The knowledge of bone biology has largely changed in the last few decades. Osteocytes are
multifunctional bone cells that are surrounded by mineralized bone matrix and for decades it …

Complete or partial edentulism in children is an uncommon occurrence. There are both
congenital and acquired conditions that may result in edentulism in the growing patient. The …

Context Antiresorptive therapy significantly reduces fracture risk in patients with benign bone
disease and skeletal-related events (SREs) in patients with bone metastases (BM) …

Background This narrative review of osteonecrosis of the jaw in patients with low bone mass
receiving treatment with antiresorptive agents is based on an appraisal of the literature by an …